Exhibit 10.1


 





STOCK PURCHASE AGREEMENT


 


This Stock Purchase
Agreement (“Agreement”) is made and entered into on September 6, 2016 (“Effective Date”),
by and between Immune Pharmaceuticals Inc., a Delaware corporation
(“Company”), and the investor whose name appears on the signature page hereto (“Investor”).


 


Recitals


 


A.The parties
desire that, upon the terms and subject to the conditions herein, Investor will purchase $2 million in shares of Common Stock at
$0.50 per share; and


 


B.The offer
and sale of the Shares provided for herein are being made pursuant to an effective Registration Statement on Form S-3 under the
Act, File No. 333-198647.


 


Agreement


 


In consideration of
the foregoing, the receipt and adequacy of which are hereby acknowledged, Company and Investor agree as follows:


 


I.Definitions.
In addition to the terms defined elsewhere in this Agreement and the Transaction Documents, capitalized terms that are not otherwise
defined have the meanings set forth in the Glossary of Defined Terms attached hereto as Exhibit 1.


 


II.Purchase
and Sale.


 


A.Purchase
Amount. Subject to the terms and conditions herein and the satisfaction of the conditions
to Closing set forth below, Investor hereby irrevocably agrees to purchase 4,000,000 Shares of Common Stock of Company at $0.50
per share for the sum of $2,000,000.00 (“Purchase Amount”) in cash.


 


B.Deliveries.
The following documents will be fully executed and delivered at the Closing:


 


		1.	Legal Opinion, in the form attached hereto as Exhibit
2;



		 	 



		2.	Officer’s Certificate, in the form attached
hereto as Exhibit 3; and



		 	 



		3.	Secretary’s Certificate, in the form attached
hereto as Exhibit 4.



 


C.Closing
Conditions. The consummation of the transactions contemplated by this Agreement (“Closing”)
is subject to the satisfaction of each of the following conditions:


 


1.All documents,
instruments and other writings required to be delivered by Company to Investor pursuant to any provision of this Agreement or in
order to implement and effect the transactions contemplated herein have been fully executed and delivered, including without limitation
those enumerated in Section II.B above;


 






    	 	 



     


    




 


3.The representations
and warranties of Company and Investor set forth in this Agreement are true and correct in all material respects as if made on
such date (except for representations and warranties expressly made as of a specified date, which shall be true as of such date);


 


4.No material
breach or default has occurred under any Transaction Document;


 


5.Company
has the number of duly authorized shares of Common Stock
reserved for issuance as required pursuant to the terms of this Agreement;


 





6.There is
not then in effect any law, rule or regulation prohibiting or restricting the transactions contemplated in any Transaction Document,
or requiring any consent or approval which will not have been obtained except for the Approval, nor is there any pending or, to
Company’s knowledge threatened, proceeding or investigation which may have the effect of prohibiting or adversely affecting
any of the transactions contemplated by this Agreement; no statute, rule, regulation, executive order, decree, ruling or injunction
will have been enacted, entered, promulgated or adopted by any court or governmental authority of competent jurisdiction that prohibits
the transactions contemplated by this Agreement, and no actions, suits or proceedings will be in progress, pending or, to Company’s
knowledge threatened, by any person other than Investor or any Affiliate of Investor, that seek to enjoin or prohibit the transactions
contemplated by this Agreement;


 


7.Any
rights of first refusal, preemptive rights, rights of participation, or any similar right to participate in the transactions contemplated
by this Agreement, if any, have been waived in writing; and


 


8.The Registration
Statement is current and effective, and a Prospectus Supplement with regard to the offer and sale of all Shares pursuant to this
Agreement has been timely filed with the Commission.


 


D.Closing.
Immediately when all conditions set forth in Section II.C have been fully satisfied, Company
will sell 4,000,000 Shares to Investor by issuing and delivering the Shares to a DTC account designated by Investor, and Investor
will purchase the Shares by payment to Company of $2,000,000.00 in cash, by wire transfer of immediately available funds to an
account designated by Company.


 


III.Representations
and Warranties.


 


A.Representations
of Company. Except as set forth under the corresponding section of the Disclosure Schedules,
if any, Company hereby represents and warrants to, and as applicable covenants with, Investor as of the Closing:


 


1.Organization
and Qualification. Company and each Subsidiary is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, as applicable, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither Company
nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation,
bylaws or other organizational or charter documents, except as would not reasonably be expected to result in a Material Adverse
Effect. Each of Company and each Subsidiary is duly qualified to conduct business and is in good standing as a foreign corporation
or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, would not reasonably be expected
to result in a Material Adverse Effect and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
or seeking to revoke, limit or curtail such power and authority or qualification.


 






    	 	 2	 



     


    

 


2.Authorization;
Enforcement. Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by each of the Transaction Documents and otherwise to carry out its obligations hereunder or thereunder. The execution and delivery
of each of the Transaction Documents by Company and the consummation by it of the transactions contemplated hereby or thereby have
been duly authorized by all necessary action on the part of Company and no further consent or action is required by Company. Each
of the Transaction Documents has been, or upon delivery will be, duly executed by Company and, when delivered in accordance with
the terms hereof, will constitute the valid and binding obligation of Company, enforceable against Company in accordance with its
terms, except (a) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium
and other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (c) insofar as indemnification and
contribution provisions may be limited by applicable law.


 


3.No Conflicts.
The execution, delivery and performance of the Transaction Documents by Company, the issuance and sale of the Shares and the consummation
by Company of the other transactions contemplated thereby do not and will not (a) conflict with or violate any provision of Company’s
or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, (b) conflict
with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any Lien upon any of the properties or assets of Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility,
debt or other instrument (evidencing Company or Subsidiary debt or otherwise) or other understanding to which Company or any Subsidiary
is a party or by which any property or asset of Company or any Subsidiary is bound or affected, (c) conflict with or result in
a violation of any material law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which Company or a Subsidiary is subject (including U.S. federal and state securities laws and regulations), or by
which any property or asset of Company or a Subsidiary is bound or affected, or (d) conflict with or violate the terms of any material
agreement by which Company or any Subsidiary is bound or to which any property or asset of Company or any Subsidiary is bound or
affected; except in the case of each of clauses (b), (c) and (d), such as would not reasonably be expected to result in a Material
Adverse Effect.


 


4.Litigation.
 There is no action, suit, inquiry, notice of violation,
proceeding or investigation pending or, to the knowledge of Company, threatened against or affecting Company, any Subsidiary or
any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign) (collectively, an “Action”), which would reasonably be expected to
adversely affect or challenge the legality, validity or enforceability of any of the Transaction Documents or the issuance of any
Shares hereunder. The Commission has not issued any stop order or other order suspending the effectiveness of any registration
statement filed by Company or any Subsidiary under the Exchange Act or the Act.


 






    	 	 3	 



     


    

 


5.Filings,
Consents and Approvals. Neither Company nor any Subsidiary is required to obtain any consent, waiver, authorization or
order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by Company of the Transaction Documents, other
than the Approval and required federal and state securities filings and such filings and approvals as are required to be made or
obtained under the applicable Trading Market rules in connection with the transactions contemplated hereby, each of which has been,
or if not yet required to be filed will be, timely filed.


 


6.Issuance
of Shares. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens. Company has reserved and will continue
to reserve from its duly authorized capital stock sufficient shares of its Common Stock for issuance pursuant to the Transaction
Documents.


 


7.Disclosure;
Non-Public Information. Company will issue a press release and file a current report on Form 8-K by 8:30 am on the Trading
Day immediately after the Effective Date describing the material terms and conditions of this Agreement, each in the form provided
to Investor prior to the Effective Date. Notwithstanding any other provision, except with respect to information that must be,
and only to the extent that it actually is, timely publicly disclosed by Company pursuant to the foregoing sentence, neither Company
nor any other Person acting on its behalf has provided Investor or its representatives, agents or attorneys with any information
that constitutes or might constitute material, non-public information, including without limitation this Agreement and the Exhibits
and Disclosure Schedules hereto. No information contained in the Disclosure Schedules constitutes material non-public information.
There is no adverse material information regarding Company that has not been publicly disclosed prior to the Effective Date. Company
understands and confirms that Investor will rely on the foregoing representations and covenants in effecting transactions in securities
of Company. All disclosure provided to Investor regarding Company, its business and the transactions contemplated hereby, including
without limitation the Prospectus Supplement and Disclosure Schedules, taken as a whole, furnished by or on behalf of Company with
respect to the representations and warranties made herein are true and correct in all material respects and do not contain any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading.


 


8.No Integrated
Offering. Neither Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this
offering to be integrated with prior offerings by Company that cause a violation of the Act or any applicable stockholder approval
provisions, including, without limitation, under the rules and regulations of the Trading Market.


 






    	 	 4	 



     


    

 


9.  Financial
Condition. Based on the financial condition of Company and its projected operating and capital requirements,
effective as of the Effective Date, the Company will require additional capital to carry on its business as now conducted and as
proposed to be conducted. Company does not incur debts beyond its ability to pay such debts as they mature, taking into account
the timing and amounts of cash to be payable on or in respect of its debt. The Public Reports set forth as of the dates thereof
all outstanding secured and unsecured Indebtedness of Company or any Subsidiary, or for which Company or any Subsidiary has commitments,
and any material default with respect to any Indebtedness.


 


 10.Section
5 Compliance. No representation or warranty or other statement made by Company in
the Transaction Documents contains any untrue statement or omits to state a material fact necessary to make any of them, in light
of the circumstances in which it was made, not misleading. Company is not aware of any facts or circumstances that would cause
the transactions contemplated by the Transaction Documents, when consummated, to violate Section 5 of the Act or other federal
or state securities laws or regulations.


 


11.Investment
Company. Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Preferred Shares,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. Company will conduct its business in a manner so that it will not become subject to the Investment Company Act.


 


12.Acknowledgments
Regarding Investor. Company’s decision to enter into this Agreement has been based solely on the independent evaluation
of Company and its representatives, and Company acknowledges and agrees that:


 


a.Investor
is not, has never been, and as a result of the transactions contemplated by the Transaction Documents will not become an officer,
director, insider, control person, to Company’s knowledge 10% or greater shareholder, or otherwise an affiliate of Company
as defined under Rule 12b-2 of the Exchange Act;


 


b.Investor
does not make or has not made any representations, warranties or agreements with respect to the Shares, this Agreement, or the
transactions contemplated hereby other than those specifically set forth in Section III.C below; and


 


c.Investor
is acting solely in the capacity of arm’s length purchaser with respect to this Agreement and the transactions contemplated
hereby; neither Investor nor any of its Affiliates, agents or representatives has or is acting as a legal, financial, investment,
accounting, tax or other advisor to Company, or fiduciary of Company, or in any similar capacity; neither Investor nor any of its
Affiliates, agents or representatives has provided any legal, financial, investment, accounting, tax or other advice to Company;
any statement made in connection with this Agreement or the transactions contemplated hereby is not advice or a recommendation,
and is merely incidental to Investor’s purchase of the Shares.


 






    	 	 5	 



     


    

 


13.Registration
Statement. The Registration Statement is current and effective, and a Prospectus Supplement with regard to the offer and
sale of all Shares pursuant to this Agreement will be filed with the Commission within two Trading Days of the Effective Date.


 


14.Certain
Fees. No brokerage or finder’s fees or commissions are or will be payable to any broker, financial advisor or consultant,
finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement.
Notwithstanding any other provision, Investor will have no obligation with respect to any fees or with respect to any claims made
by or on behalf of other Persons for fees of a type contemplated in this section that may be due in connection with the transactions
contemplated by this Agreement or the other Transaction Documents.


 


15.Powers of
Attorney. There are no outstanding powers of attorney executed on behalf of the Company or any Subsidiary.


 


C.Representations
and Warranties of Investor. Investor hereby represents and warrants to Company as of the
Closing as follows:


 


1.Organization;
Authority. Investor is an entity validly existing and in good standing under the laws of the jurisdiction of its organization
with full right, company power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations thereunder. The execution, delivery and performance by Investor of the transactions
contemplated by this Agreement have been duly authorized by all necessary company or similar action on the part of Investor. Each
Transaction Document to which it is a party has been, or will be, duly executed by Investor, and when delivered by Investor in
accordance with the terms hereof, will constitute the valid and legally binding obligation of Investor, enforceable against it
in accordance with its terms, except (a) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (b) as limited by
laws relating to the availability of specific performance, injunctive relief or other equitable remedies, and (c) insofar as indemnification
and contribution provisions may be limited by applicable law.


 


2.Investor
Status.  At the time Investor was offered the Shares, it was, and at the Effective Date it is: (a) an accredited investor
as defined in Rule 501(a) under the Act; and (b) not a registered broker-dealer, member of FINRA, or an affiliate thereof.


 


3.Experience
of Investor. Investor, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares,
and has so evaluated the merits and risks of such investment. Investor is able to bear the economic risk of an investment in the
Shares and, at the present time, is able to afford a complete loss of such investment.


 


4.Ownership.
 Investor is acquiring the Preferred Shares as principal for its own account. Investor will not engage in hedging transactions
with regard to the Shares unless in compliance with the Act, and will resell the Shares only pursuant to registration under the
Act or an available exemption therefrom.


 


5.No Short
Sales. Neither Investor nor any Affiliate holds any short position in, nor has engaged in any Short Sales of the Common
Stock, or engaged in any hedging transactions with regard to the Shares prior to the Effective Date.  


 






    	 	 6	 



     


    

 


IV.Securities
and Other Provisions.


 


A.Investor
Due Diligence. Investor will have the right and opportunity to conduct customary due diligence
with respect to any Registration Statement or Prospectus in which the name of Investor or any Affiliate of Investor appears.


 


B.Integration.
Company will not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security, as defined in
Section 2 of the Act, that would be integrated with the offer or sale of the Shares to Investor for purposes of the rules and regulations
of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.


 


C.Disclosure
and Publicity. Company will notify Investor prior to issuing any current report, press release,
public statement or communication with respect to the transactions contemplated hereby.


 


D.Shareholders
Rights Plan.  No claim will be made or enforced by Company or, to the knowledge of Company,
any other Person that Investor is an “Acquiring Person” under any shareholders rights plan or similar plan or arrangement
in effect or hereafter adopted by Company, or that Investor could be deemed to trigger the provisions of any such plan or arrangement,
in either such case, by virtue of receiving Shares under the Transaction Documents or under any other agreement between Company
and Investor. Company will conduct its business in a manner so that it will not become subject to the Investment Company Act of
1940, as amended.


 


E.No Non-Public
Information. Company covenants and agrees that neither it nor any other Person acting on
its behalf will, provide Investor or its agents or counsel with any information that Company believes or reasonably should believe
will constitute material non-public information after Closing. On and after Closing, neither Investor nor any Affiliate of Investor
will have any duty of trust or confidence that is owed directly, indirectly, or derivatively, to Company or the stockholders of
Company, or to any other Person who is the source of material non-public information regarding Company. Company understands and
confirms that Investor will be relying on the foregoing in effecting transactions in securities of Company, including without limitation
sales of the Shares.


 






    	 	 7	 



     


    

 


F.Indemnification
of Investor.


 


1.Obligation
to Indemnify. Subject to the provisions of this Section IV.G,
Company will indemnify and hold Investor, its Affiliates, managers and advisors, and each of their officers, directors, shareholders,
partners, employees, representatives, agents and attorneys, and any person who controls Investor within the meaning of Section
15 of the Act or Section 20 of the Exchange Act (collectively, “Investor Parties”
and each a “Investor Party”), harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, reasonable costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys’ fees and costs of investigation (collectively, “Losses”)
that any Investor Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties,
covenants or agreements made by Company in this Agreement or in the other Transaction Documents, (b) any untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, Prospectus, Prospectus Supplement,
or any information incorporated by reference therein, or arising
out of or based upon any omission or alleged omission to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading, or (c) any action by a creditor or stockholder of
Company who is not an Affiliate of an Investor Party, challenging the transactions contemplated by the Transaction Documents; provided,
however, that Company will not be obligated to indemnify any Investor Party for any Losses finally adjudicated to be caused solely
by (i) a false statement of material fact contained within written information provided by such Investor Party expressly for the
purpose of including it in the applicable Registration Statement, Prospectus, Prospectus Supplement, or (ii) such Investor Party’s
unexcused material breach of an express provision of this Agreement or another Transaction Document.



 


2.Procedure
for Indemnification. If any action will be brought against an Investor Party in respect of which indemnity may be sought
pursuant to this Agreement, such Investor Party will promptly notify Company in writing, and Company will have the right to assume
the defense thereof with counsel of its own choosing. Investor Parties will have the right to employ separate counsel in any such
action and participate in the defense thereof, but the reasonable fees and expenses of such counsel will be at the expense of Investor
Parties except to the extent that (a) the employment thereof has been specifically authorized by Company in writing, (b) Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (c) in such action there is, in the
reasonable opinion of such separate counsel, a material conflict with
respect to the dispute in question on any material issue between the position of Company and the position of
Investor Parties such that it would be inappropriate for one counsel to represent Company and Investor Parties. Company
will not be liable to Investor Parties under this Agreement (i) for any settlement by an Investor Party effected without Company’s
prior written consent, which will not be unreasonably withheld or delayed; or (ii) to the extent, but only to the extent that a
loss, claim, damage or liability is either attributable to
Investor’s breach of any of the representations, warranties, covenants or agreements made by Investor in this Agreement or
in the other Transaction Documents. In no event will the Company be liable for the reasonable fees and expenses for more than one
separate firm of attorneys (plus local counsel as applicable) to represent all Investor Parties.


 


3.Other
than the liability of Investor to Company for uncured material breach of the express provisions of this Agreement,
no Investor Party will have any liability to Company or any Person asserting claims on behalf of or in right of Company as a result
of acquiring the Shares under this Agreement.


 


H.No Shorting.
For so long as Investor holds any Shares, neither Investor nor any of its Affiliates will engage in or effect, directly or indirectly,
any Short Sale of Common Stock. For the avoidance of doubt, selling against delivery of Shares is not a Short Sale. There will
be no restriction or limitation of any kind on Investor’s right or ability to sell or transfer any or all of the Shares at
any time, in its sole and absolute discretion. 


 






    	 	 8	 



     


    

 


I.Stock
Splits. If Company at any time on or after the Effective Date subdivides (by any stock split,
stock dividend, recapitalization or otherwise) or combines (by combination, reverse stock split or otherwise) one or more classes
of its outstanding shares of Common Stock into a greater or lesser number of shares, the share numbers, prices and other amounts
set forth in this Agreement, as in effect immediately prior to such subdivision or combination, will be proportionately reduced
or increased, as applicable, effective at the close of business on the date the subdivision or combination becomes effective. 


 


J.Issuance
Limitation. Notwithstanding any other provision, at no time may Company issue Shares to Investor
which, when aggregated with all other shares of Common Stock then deemed beneficially owned by Investor, would result in Investor
owning more than 4.99% of all Common Stock outstanding immediately after giving effect to such issuance, as determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. No provision of this paragraph may
be waived by Investor or Company.


 


V.General Provisions.


 


A.Notice.
Unless a different time of day or method of delivery is specifically provided in the Transaction Documents, any and all notices
or other communications or deliveries required or permitted to be provided hereunder will be in writing and will be deemed given
and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or electronic
mail prior to 5:00 p.m. Eastern time on a Trading Day and an electronic confirmation of delivery is received by the sender, (b)
the next Trading Day after the date of transmission, if such notice or communication is delivered later than 5:00 p.m. Eastern
time or on a day that is not a Trading Day, (c) the next Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given. The
addresses for such notices and communications are such other address as may be designated in writing, in the same manner, by such
Person.


 


B.Amendments;
Waivers. No provision of this Agreement may be waived or amended except in a written instrument
signed, in the case of an amendment, by Company and Investor or, in the case of a waiver, by the party against whom enforcement
of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement
will be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor will any delay or omission of either party to exercise any right hereunder in any manner impair
the exercise of any such right.


 


C.No Third-Party
Beneficiaries. Except as otherwise set forth in Section IV.G,
this Agreement and the Transaction Documents will inure solely to the benefit of the parties hereto, and is not for the benefit
of, nor may any provision hereof be enforced by, any other Person. A Person who is not a party to this Agreement shall not have
any rights under the Contracts (Rights of Third Parties) Law, 2014 of the Cayman Islands to enforce any term of this Agreement
or any Transaction Document.


 






    	 	 9	 



     


    

 


D.Fees
and Expenses. Except as otherwise provided in this Agreement, each party will pay the fees
and expenses of its own advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of the Transaction Documents. Company acknowledges
and agrees that Investor’s counsel solely represents Investor, and does not represent Company or its interests in connection
with the Transaction Documents or the transactions contemplated thereby. Company will pay all stamp and other taxes and duties,
if any, levied in connection with the sale or issuance of the Shares to Investor.


 


E.Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement will not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, will incorporate
such substitute provision in this Agreement.


 


F.Governing
Law. All matters between the parties, including without limitation questions concerning the
construction, validity, enforcement and interpretation of the Transaction Documents will be governed by and construed and enforced
in accordance with the laws of the Cayman Islands, without regard to the principles of conflicts of law that would require or permit
the application of the laws of any other jurisdiction, except for corporation law matters applicable to Company which will be governed
by the corporate law of its jurisdiction of formation. The parties hereby waive all rights to a trial by jury. In any action, arbitration
or proceeding, including appeal, arising out of or relating to any of the Transaction Documents or otherwise involving the parties,
the prevailing party will be awarded its reasonable attorneys’ fees and other costs and expenses reasonably incurred in connection
with the investigation, preparation, prosecution or defense of
such action or proceeding.


 


G.Arbitration.
Any dispute, controversy, claim or action of any kind arising out of, relating to, or in connection with this Agreement, or in
any way involving Company and Investor or their respective Affiliates, including any issues of arbitrability, will be resolved
solely by final and binding arbitration in English before a retired judge at JAMS International, or its successor, in the Territory
of the Virgin Islands, pursuant to the most expedited and Streamlined Arbitration Rules and Procedures available. Any interim or
final award may be entered and enforced by any court of competent jurisdiction. The final award will include the prevailing party’s
reasonable arbitration, expert witness and attorney fees, costs and expenses.


 








H.Payment
Set Aside. To the extent that Company makes a payment or payments to Investor pursuant to
any Transaction Document or Investor enforces or exercises its rights thereunder, and such payment or payments or the proceeds
of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set
aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to Company, a trustee, receiver
or any other person under any law, including, without limitation, any bankruptcy law, state or federal law, common law or equitable
cause of action, then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied
will be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not
occurred.


 






    	 	 10	 



     


    

  


I.Headings.
The headings herein are for convenience only, do not constitute a part of this Agreement and will not be deemed to limit or affect
any of the provisions hereof


 


J.Time
of the Essence.  Time is of the essence with respect to all provisions of this Agreement.


 


K.Survival.
 The representations and warranties contained herein will survive the Closing and the delivery
of the Shares.


 


L.Construction.
 The parties agree that each of them and/or their respective counsel has reviewed and had an
opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities
are to be resolved against the drafting party will not be employed in the interpretation of the Transaction Documents or any amendments
hereto. The language used in this Agreement will be deemed to be the language chosen
by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. All currency
references in any Transaction Document are to U.S. dollars.


 


M.Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together will be considered one and the same
agreement and will become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by portable document
format, facsimile or electronic transmission, such signature will create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.


 


N.Entire
Agreement. This Agreement, including the Exhibits hereto,
which are hereby incorporated herein by reference, contains the entire agreement and understanding of the parties,
and supersedes all prior and contemporaneous agreements, term sheets,
letters, discussions, communications and understandings, both oral and written,
which the parties acknowledge have been merged into this Agreement. No party, representative, advisor, attorney or agent
has relied upon any collateral contract, agreement, assurance, promise, understanding, statement or representation not expressly
set forth herein. The parties hereby absolutely, unconditionally and irrevocably waive all rights and remedies, at law and in equity,
directly or indirectly arising out of or relating to, or which may arise as a result of, any Person’s reliance on any such
statement or assurance.


 






    	 	 11	 



     


    

 


IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories on the Effective Date.


  


	Company:	 
	 	 	 
	IMMUNE PHARMACEUTICALS INC.
	 	 	 
	 	 	 
	By:  	 	 
	Name:  	 	 
	Title:  	 	 
	 	 	 
	 	 	 
	By:  	 	 
	Name:  	 	 
	Title:  	 	 
	 	 	 
	 	 	 
	Investor:	 
	 	 	 
	 	 	 
	 	 
	Investor Name	 
	 	 	 
	 	 	 
	By:  	 	 
	Name:  	 	 
	Title:  	 	 
	 	 	 
	 	 	 
	By:  	 	 
	Name:  	 	 
	Title:  	 	 







 




    	 	 12	 



     


    

 


Exhibit 1


 


Glossary of Defined Terms


 


“$”
means the currency of the United States of America, in which all dollar amounts in the Transaction Documents will be expressed.


 


“Act”
means the U.S. Securities Act of 1933, as amended, and the rules and regulations promulgated by the Commission thereunder.


 


“Action”
has the meaning set forth in Section III.A.4.


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common
control with a Person, as such terms are used in and construed under Rule 144 under the Act.


 


“Agreement”
means this Stock Purchase Agreement.


 


“Closing”
has the meaning set forth in Section II.D.


 


“Commission”
means the U.S. Securities and Exchange Commission.


 


“Common Stock”
means the Common Stock of Company and any replacement or substitute thereof, or any share capital into which such Common Stock
will have been changed or any share capital resulting from a reclassification of such Common Stock.


 


“Company”
has the meaning set forth in the first paragraph of the Agreement.


 


“Disclosure
Schedules” means the disclosure schedules of Company delivered concurrently herewith. The Disclosure Schedules will contain
no material non-public information.


 


“DTC”
means The Depository Trust Company, or any successor performing substantially the same function for Company.


 


“Exchange
Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated by the Commission
thereunder.


 


“Effective
Date” has the meaning set forth in the first paragraph of the Agreement.


 


“Legal Opinion”
means an opinion from Company’s independent legal counsel, in the form attached as Exhibit 2.


 


“Officer’s
Certificate” means a certificate executed by an authorized officer of Company, in the form attached as Exhibit 3.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government, or an agency or subdivision thereof, or other entity of any kind.


 






    	 	 13	 



     


    

 


“Prospectus”
means the final prospectus filed for the Registration Statement.


 


“Prospectus
Supplement” means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with
the Commission and delivered by the Company to Investor.


 


“Public Reports”
includes all reports filed by Company under the Act or the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the two full fiscal years preceding the Effective Date and thereafter.


 


“Purchase
Amount”has the meaning set forth in Section
II.A.1


 


“Investor”
has the meaning set forth in the first paragraph of the Agreement.


 


“Registration
Statement” means the “shelf” registration statement on Form S-3 (File No. 333-198647) filed under the Act
with the Commission, and such amendments as may have been required to the date of this Agreement, which has been declared effective
by the Commission on October 28, 2014, and, at any given time, including amendments thereto to such time, the exhibits and any
schedules thereto at such time, the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Act at
such time, and the documents and information otherwise deemed to be a part thereof or included therein by Rule 430B under the Act
or otherwise pursuant to the Act at such time.


 


“Secretary’s
Certificate” means a certificate, in the form attached as Exhibit 4, signed by the secretary of Company.


 


“Shares”
means shares of Common Stock of the Company to be issued to Investor pursuant to this Agreement.


 


“Short Sale”
means a “short sale” as defined in Rule 200 of Regulation SHO of the Exchange Act.


 


“Subsidiary”
means any Person Company owns or controls, or in which Company, directly or indirectly, owns a majority of the capital stock or
similar interest that would be disclosable pursuant to Regulation S-K, Item 601(b)(21).


 


“Trading
Day” means any day on which the Common Stock is traded on the Trading Market; provided
that it will not include any day on which the Common Stock is (a) scheduled to trade for less than 5 hours, or (b) suspended from
trading.


 


“Transaction
Documents” means this Agreement, the other agreements, certificates and documents referenced herein or the form of which
is attached hereto, and the exhibits, schedules and appendices hereto and thereto. 


 




    	 	 14	 



     


    

 


Exhibit 2


 


Form of Legal Opinion


 


 


1.The Company is a corporation
validly existing and in good standing under the laws of the state of its incorporation.


 


2.The Company has
the requisite corporate power and authority to execute, deliver and perform its obligations under the Transaction Documents, to
sell and issue shares of Common Stock under the Purchase Agreement (the “Shares”).


 


3.The Shares have
been duly authorized by the Company, and upon issuance and delivery against payment therefor in accordance with the terms of the
Purchase Agreement, the Shares will be validly issued, fully paid and nonassessable. Such issuance of the Shares will not be subject
to any statutory or, to our knowledge, contractual preemptive rights of any stockholder of the Company.


 


4.The execution,
delivery and performance of the Transaction Documents have been duly authorized by all necessary corporate action on the part of
the Company, and the Transaction Documents have been duly executed and delivered by the Company.


 


5.Each Transaction
Document constitutes a valid and binding agreement of the Company enforceable against the Company in accordance with its terms,
except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement, moratorium or other similar
laws affecting creditors’ rights, and subject to general equity principles and to limitations on availability of equitable
relief, including specific performance.


 


6.The execution
and delivery of the Transaction Documents by the Company does not, and the Company’s performance of its obligations thereunder
will not (a) violate the Certificate of Incorporation or the Bylaws, each as in effect on the date hereof, (b) violate in any material
respect any federal or New York or Delaware state law, rule or regulation, or judgment, order or decree of any state or federal
court or governmental or administrative authority, in each case that, to our knowledge, is applicable to the Company or its properties
or assets (except to the extent such violation would not have a material adverse effect on the Company’s business, properties,
assets, financial condition or results of operations or prevent the performance by the Company of any material obligation under
the Transaction Documents), or (c) to our knowledge, require the authorization, consent, approval of or other action of, notice
to or filing or qualification with, any New York or Delaware state or federal governmental authority, except (i) as have been,
or will be prior to the Closing, duly obtained or made, (ii) any filings which may be required under applicable federal securities,
state securities or blue sky laws and (iii) the filing of a proxy statement with respect to the Approval, except to the extent
failure to be so obtained or made would not have a material adverse effect on the Company’s business, properties, assets,
financial condition or results of operations or its ability to consummate the transactions contemplated under the Transaction Documents.


 






     


     


    

 


7.The Company is
not, and immediately after the consummation of the transactions contemplated by the Transaction Documents will not be, an investment
company within the meaning of Investment Company Act of 1940, as amended.


 


8.To our knowledge,
there is no claim, action, suit, proceeding, arbitration, investigation or inquiry, pending or threatened, before any court or
governmental or administrative body or agency, or any private arbitration tribunal, against the Company that challenges the validity
or enforceability of, or seeks to enjoin the performance of, the Transaction Documents.


 


9.The Registration
Statement filed with the Commission, which registers the sale of the Shares to Investor is current and effective as of the date
hereof.


 







     


     


    

 


Exhibit 3


 


Form of Officer’s Certificate


  


 


IMMUNE PHARMACEUTICALS INC.


 


September 6, 2016


 


The undersigned hereby certifies that:


 


The undersigned is
the duly appointed Chief Executive Officer of Immune Pharmaceuticals Inc., a Delaware corporation (“Company”).


 


This Officer’s
Certificate (“Certificate”) is being delivered to ____________________ (“Investor”), by Company,
to fulfill the requirement under the Stock Purchase Agreement, dated September 6, 2016, between Investor and Company (“Agreement”).
Terms used and not defined in this Certificate have the meanings set forth in the Agreement.


 


The representations
and warranties of Company set forth in the Agreement are true and correct in all material respects as if made on the above date
(except for any representations and warranties that are expressly made as of a particular date, in which case such representations
and warranties will be true and correct as of such particular date), and no default has occurred under the Agreement, or any other
agreement with Investor or any Affiliate of Investor.


 


Company is not, and
will not be as a result of the Closing, in default of the Agreement, any other agreement with Investor or any Affiliate of Investor.


 


All of the conditions
to the Closing required to be satisfied by Company prior to the Closing have been satisfied in their entirety.


 


IN WITNESS WHEREOF,
the undersigned has executed this Officer’s Certificate as of the date set forth above.


 


 





	Signed:  	 	 
	Name:  	 	 
	Title: 	 	 







 




     


     


    

 


Exhibit 4


 


Form of Secretary’s Certificate


 


 


 


September 6, 2016


 


The undersigned hereby certifies that:


 


The undersigned is
the duly appointed Secretary of Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”).


 


This Secretary’s
Certificate (“Certificate”) is being delivered to ____________________ (“Investor”), by Company,
to fulfill the requirement under the Stock Purchase Agreement, dated September 6, 2016, between Investor and Company (“Agreement”).
Terms used and not defined in this Certificate have the meanings set forth in the Agreement.


 


The Certificate of
Incorporation of Company, as in effect on the Effective Date, is the same as previously provided to Investor.


 


The Bylaws of Company,
as in effect on the Effective Date, are the same as previously provided to Investor.


 


Attached hereto as
Exhibit “A” is a true, correct and complete copy of the resolutions of the Board of Directors of Company authorizing
the Agreement, the Transaction Documents, and the transactions contemplated thereby. Such resolutions have not been amended or
rescinded and remain in full force and effect as of the date hereof.


 


IN WITNESS WHEREOF,
the undersigned has executed this Secretary’s Certificate as of the date set forth above.


 


 





	Signed:  	 	 
	Name:  	 	 
	Title: